Anti-fatigue effervescent tablet, preparation method and application thereof

Abstract

The application discloses an anti-fatigue effervescent tablet and a preparation method and application thereof, and belongs to the field of food processing. The anti-fatigue effervescent tablet comprises, in mass parts, 40-100 parts of L-carnitine, 15-38 parts of taurine, 1-2 parts of a compound vitamin B group, 40-100 parts of a binder, 35-55 parts of a disintegrating agent, 97.08-160.2 parts of a taste regulator and 35-65 parts of a filling agent. The preparation method comprises granulating an acid source and a base source respectively, controlling the water content of the acid granules and the base granules to be less than 0.5%, and then compressing the mixture into tablets. The anti-fatigue effervescent tablet can significantly prolong the exhaustive swimming time of mice, has excellent anti-fatigue effect, and the disintegration time is within 200 seconds. Meanwhile, the problem of stickiness and rush caused by the hygroscopicity of L-carnitine is effectively solved, the tablet is complete, the surface is smooth, and the taste is good.

Description

Technical Field

[0001] This invention belongs to the field of food processing, specifically relating to an anti-fatigue effervescent tablet, its preparation method, and its application. Background Technology

[0002] The information disclosed in this background section is intended only to enhance understanding of the overall background of the invention and is not necessarily to be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.

[0003] Effervescent tablets are a new type of tablet, typically composed of a disintegrant system of organic acids and carbonates (bicarbonates). Upon contact with water, they undergo a rapid neutralization reaction, generating and releasing a large amount of carbon dioxide gas, which accelerates the tablet's disintegration. Effervescent tablets offer advantages such as rapid disintegration, quick absorption, portability, and ease of administration, and are widely used in pharmaceutical preparations and health foods. Combining multiple functional ingredients into effervescent tablets not only provides additional fluid intake but also achieves the intended nutritional supplementation or therapeutic value, demonstrating a broad market prospect.

[0004] Currently, most energy supplements or anti-fatigue products on the market are liquid beverages or granules. Liquid beverages are inconvenient to carry and difficult to preserve after opening; while granules are easy to carry, they need to be stirred to dissolve before consumption, making them less convenient. Effervescent tablets combine the advantages of being both convenient to carry and easy to take.

[0005] L-carnitine is an amino acid derivative whose main function is to promote the entry of fatty acids into mitochondria for oxidation and energy supply. It has the effects of controlling body fat, maintaining healthy blood lipid levels, and relieving physical fatigue. It's found everywhere, from sports supplements to weight-loss coffees. However, L-carnitine has strong hygroscopic properties, easily absorbing moisture from the air during the preparation of effervescent tablets, leading to sticking and impaction during compression, affecting tablet formation and appearance quality. Solving the sticking and impaction problem caused by L-carnitine's moisture absorption while ensuring rapid disintegration of effervescent tablets is a pressing technical challenge in the development of such products. Summary of the Invention

[0006] To address the technical problems mentioned above, this invention provides an anti-fatigue effervescent tablet, its preparation method, and its application.

[0007] The present invention adopts the following technical solution: In a first aspect, the present invention provides an anti-fatigue effervescent tablet comprising, by weight: 40-100 parts of L-carnitine, 15-38 parts of taurine, 1-2 parts of B vitamins, 40-100 parts of binder, 35-55 parts of disintegrant, 97.08-160.2 parts of flavor modifier, and 35-65 parts of filler.

[0008] A second aspect of the present invention provides a method for preparing the anti-fatigue effervescent tablets described in the first aspect, comprising: Each solid raw material is dried until the moisture content is less than 0.5%, sieved, and weighed according to the proportion; Disintegrants, flavor modifiers, vitamin B12 and some binders are added to purified water to make a wet soft material, which is then dried until the moisture content is less than 0.5% to obtain alkali particles; The flavor modifier, taurine, L-carnitine, vitamin B1, vitamin B2, vitamin B3, vitamin B5 and vitamin B6 are mixed evenly, and then mixed evenly with some binder and purified water. After drying, they are pulverized until the moisture content is less than 0.5% to obtain acid granules. The acid and alkali granules are granulated, mixed, and then filled with filler and compressed into tablets to obtain the final product.

[0009] A third aspect of the present invention provides the use of the anti-fatigue effervescent tablets described in the first aspect in the preparation of products for anti-fatigue purposes.

[0010] Compared with the prior art, the beneficial effects of the present invention are: The anti-fatigue effervescent tablets of this invention, through a specific ratio of L-carnitine, taurine, and B-complex vitamins, can significantly prolong the exhaustive swimming time of mice. These effervescent tablets disintegrate rapidly in water, with disintegration times all within 200 seconds, meeting the requirements of the Chinese Pharmacopoeia for effervescent tablet disintegration time, facilitating rapid consumption by consumers. Furthermore, by optimizing the ratio of L-carnitine to excipients and controlling the moisture content of both acid and alkali granules to below 0.5% during the preparation process, the sticking and disintegration phenomenon caused by the hygroscopic nature of L-carnitine is effectively alleviated. The resulting tablets are intact, have a smooth surface, and exhibit a high yield rate. Detailed Implementation

[0011] It should be noted that the following detailed description is illustrative and intended to provide further explanation of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0012] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of exemplary embodiments according to the invention. As used herein, the singular form is intended to include the plural form as well, unless the context clearly indicates otherwise. Furthermore, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.

[0013] In a typical embodiment of the present invention, an anti-fatigue effervescent tablet is provided, wherein the anti-fatigue effervescent tablet comprises, by weight: 40-100 parts of L-carnitine, 15-38 parts of taurine, 1-2 parts of B complex vitamins, 40-100 parts of binder, 35-55 parts of disintegrant, 97.08-160.2 parts of flavor modifier, and 35-65 parts of filler.

[0014] In some embodiments, the anti-fatigue effervescent tablets comprise, by weight: 55-95 parts L-carnitine, 20-35 parts taurine, 1.15-1.48 parts B complex vitamins, 50-95 parts binder, 40-50 parts disintegrant, 105.1-149 parts flavor modifier, and 40-60 parts filler.

[0015] In some embodiments, the flavor modifier includes steviol glycosides, citric acid, and apple powder.

[0016] In some embodiments, an anti-fatigue effervescent tablet is provided, which comprises, by weight, 40-100 parts of L-carnitine, 15-38 parts of taurine, 1-2 parts of B vitamins, 40-100 parts of binder, 35-55 parts of disintegrant, 0.08-3.2 parts of steviol glycosides, 35-65 parts of citric acid, 62-92 parts of apple powder, and 35-65 parts of filler.

[0017] In some embodiments, an anti-fatigue effervescent tablet is provided, which comprises, by weight, 55-95 parts of L-carnitine, 20-35 parts of taurine, 1.15-1.48 parts of B vitamins, 50-95 parts of binder, 40-50 parts of disintegrant, 0.1-2 parts of steviol glycosides, 40-60 parts of citric acid, 65-87 parts of apple powder, and 40-60 parts of filler.

[0018] In some embodiments, the B-complex vitamins include 0.10-0.20 parts of vitamin B1, 0.070-0.080 parts of vitamin B2, 0.70-0.80 parts of vitamin B3, 0.20-0.30 parts of vitamin B5, 0.070-0.080 parts of vitamin B6, and 0.010-0.020 parts of vitamin B12.

[0019] In some embodiments, the adhesive comprises one of microcrystalline cellulose, povidone K30, mannitol, polyvinylpyrrolidone, and hydroxypropyl methylcellulose.

[0020] The disintegrant includes sodium bicarbonate; the filler is maltodextrin.

[0021] This invention combines L-carnitine, taurine, and B-complex vitamins in a specific ratio to prepare an anti-fatigue effervescent tablet that rapidly disintegrates upon contact with water, effectively alleviating the stickiness caused by L-carnitine's hygroscopic nature. L-carnitine is responsible for transporting fatty acids to mitochondria, providing energy to the body; taurine stabilizes cell membranes, regulates calcium ion homeostasis, and reduces oxidative damage caused by exercise; B-complex vitamins, as coenzymes for energy metabolism, further enhance the above effects. The three components work synergistically to exert their anti-fatigue effects. A mouse weight-bearing swimming experiment demonstrated that 40-100 parts of L-carnitine significantly prolonged the exhaustive swimming time in mice (P < 0.05), while the absence of any one component resulted in no significant anti-fatigue effect. This indicates that the ratio described in this invention has an excellent synergistic effect. Furthermore, the synergistic use of apple powder, citric acid, and steviol glycosides gives the effervescent tablet a moderate sweetness and pleasant flavor, improving user compliance.

[0022] Another typical embodiment of the present invention provides a method for preparing the above-mentioned anti-fatigue effervescent tablets, comprising: Each solid raw material is dried until the moisture content is less than 0.5%, sieved, and weighed according to the proportion; Disintegrants, flavor modifiers, vitamin B12 and some binders are added to purified water to make a wet soft material, which is then dried until the moisture content is less than 0.5% to obtain alkali particles; The flavor modifier, taurine, L-carnitine, vitamin B1, vitamin B2, vitamin B3, vitamin B5 and vitamin B6 are mixed evenly, and then mixed evenly with some binder and purified water. After drying, they are pulverized until the moisture content is less than 0.5% to obtain acid granules. The acid and alkali granules are granulated, mixed, and then filled with filler and compressed into tablets to obtain the final product.

[0023] In some embodiments, the drying temperature is 40~60°C.

[0024] In some embodiments, a 70-90 mesh sieve is used for sieving.

[0025] In some embodiments, the binder portion in the alkali particles comprises 20% to 40% of the total mass of all binders, and the binder portion in the acid particles comprises 60% to 80% of the total mass of all binders.

[0026] In some embodiments, the flavor modifier in the alkali granules is apple powder.

[0027] In some embodiments, the flavor modifiers in the acid grains are steviol glycosides and citric acid.

[0028] In some embodiments, the moisture content of both the dried acid and alkali particles is less than 0.3%.

[0029] In some embodiments, acid and alkali particles are granulated and then passed through a 10-30 mesh sieve.

[0030] In some embodiments, tableting is performed using a rotary tablet press.

[0031] This invention addresses the technical challenge of L-carnitine's hygroscopic nature leading to sticking and disintegration. It employs a two-phase granulation process with separate acid and alkali phases, strictly controlling the moisture content of both acid and alkali granules to be less than 0.5%. Comparative studies show that conventional one-pot granulation methods result in severe sticking and disintegration, preventing the production of intact tablets. Furthermore, if the moisture content exceeds 0.5%, sticking and disintegration will still occur even if the moisture content of either the acid or alkali granules exceeds 0.5%. This invention successfully solves the problem of L-carnitine's hygroscopic sticking and disintegration through the above process, resulting in intact effervescent tablets that disintegrate rapidly (disintegration time <200 seconds) and exhibit significant anti-fatigue effects. Simultaneously, the preparation method of this invention is stable, simple to operate, and suitable for industrial production.

[0032] A third typical embodiment of the present invention provides an application of the above-mentioned anti-fatigue effervescent tablet in the preparation of products for anti-fatigue.

[0033] In some embodiments, the product includes one or more of the following: pharmaceutical preparations, health foods, functional solid beverages, sports nutrition supplements, and daily dietary supplements.

[0034] In some embodiments, the product is a pharmaceutical preparation, which may be formulated into tablets, granules, capsules, or oral liquids by adding pharmaceutically acceptable excipients. The pharmaceutical preparation is used to relieve physical fatigue, improve exercise endurance, and alleviate symptoms of fatigue-induced lethargy and metabolic disorders.

[0035] To enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.

[0036] Example 1: Screening of L-carnitine formulation Preparation method of anti-fatigue effervescent tablets: Weigh the raw materials according to the formula in Table 1. Place the solid raw materials, including L-carnitine, taurine, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, sodium bicarbonate, microcrystalline cellulose, citric acid, apple powder, steviol glycosides, and maltodextrin, in a vacuum drying oven at 50°C to dry them, ensuring that the moisture content of the materials is less than 0.5%. Then, pass them through an 80-mesh sieve and weigh them accurately.

[0037] Citric acid, vitamin B5, L-carnitine, taurine, vitamin B1, vitamin B2, vitamin B3, vitamin B6, and steviol glycosides were mixed evenly and then passed through a 60-mesh sieve. This mixture was then added to 70% microcrystalline cellulose and purified water and mixed thoroughly to prepare a wet soft mass. The wet granules were dried in a 50°C forced-air drying oven for 2 hours, controlling the moisture content to be less than 0.5%, to obtain acid granules.

[0038] Meanwhile, the remaining 30% of microcrystalline cellulose was moistened with purified water, and sodium bicarbonate, apple powder and vitamin B12 were added evenly, stirred evenly, dried and pulverized, with the moisture content controlled to be less than 0.5%, to obtain alkali particles.

[0039] The acid and alkali granules are sieved through a 20-mesh sieve, then maltodextrin is added and mixed evenly. The mixture is then fed into a rotary tablet press to compress the tablets, with each tablet weighing 4g. The resulting effervescent tablets are then sealed and stored.

[0040] Table 1. Formulation of the anti-fatigue effervescent tablets in Example 1

[0041] The anti-fatigue effervescent tablets prepared in Examples 1-1 to 1-5 were observed for appearance, evaluated for taste, and had their disintegration time determined according to the 2025 edition of the Chinese Pharmacopoeia. The tableting process was also observed for whether sticking or punching occurred. The results are shown in Table 2.

[0042] Table 2 Performance test results of Examples 1-1 to 1-5

[0043] Table 2 shows that when the L-carnitine content was 450 mg, 600 mg, 750 mg, and 900 mg, the effervescent tablets were intact, uniform in color, and smooth in surface, with a moderate sweetness. The disintegration time was between 183 and 192 seconds, and no sticking or bridging was observed. When the L-carnitine content increased to 1200 mg, even with the acid-base two-phase granulation method, the resulting effervescent tablets were still not intact in appearance and showed sticking or bridging, but the disintegration time and taste still met the requirements.

[0044] Example 2: Screening of Adhesives Weigh each raw material according to Table 3, with L-carnitine fixed at 750 mg, and other active ingredients as in Examples 1-3. The binders used were povidone K30 (Example 2-1), mannitol (Example 2-2), polyvinylpyrrolidone (Example 2-3), and hydroxypropyl methylcellulose (Example 2-4), each at a dosage of 650 mg. Microcrystalline cellulose was replaced with the corresponding binder, while the remaining excipients remained unchanged.

[0045] The preparation method is the same as in Example 1, except that the adhesive used is replaced according to Table 3.

[0046] Table 3 Formulations of anti-fatigue effervescent tablets in Examples 2-1 to 2-4

[0047] The anti-fatigue effervescent tablets prepared in Examples 2-1 to 2-4 were tested using the same test method as in Example 1, and the results are shown in Table 4.

[0048] Table 4 Performance test results of Examples 2-1 to 2-4

[0049] As shown in Table 4, when the binder is microcrystalline cellulose, povidone K30, mannitol, polyvinylpyrrolidone, or hydroxypropyl methylcellulose, the resulting effervescent tablets are all intact in appearance, without sticking, and disintegrate rapidly. The appropriate binder can be selected according to actual production needs.

[0050] Example 3 Screening of disintegrants Weigh each raw material according to Table 5, fix L-carnitine at 750 mg, the active ingredients are the same as in Examples 1-3, adjust the amount of sodium bicarbonate to 300 mg (Example 3-1), 400 mg (Example 3-2), and 600 mg (Example 3-3), and keep the other excipients unchanged.

[0051] The preparation method is the same as in Example 1.

[0052] Table 5. Formulations of anti-fatigue effervescent tablets in Examples 3-1 to 3-3

[0053] The anti-fatigue effervescent tablets prepared in Examples 3-1 to 3-3 were tested using the same test method as in Example 1, and the results are shown in Table 6.

[0054] Table 6 Performance test results of Examples 3-1 to 3-3

[0055] As shown in Table 6, when the amount of sodium bicarbonate is too small (7.5%), the disintegration time is as long as 356 seconds, exceeding the 5 minutes (300 seconds) specified in the pharmacopoeia; when the amount of sodium bicarbonate is too large (15%), the friability is unacceptable, and the tablets are incomplete. Therefore, the suitable dosage range of the disintegrant sodium bicarbonate is 10% to 12.5%, more preferably 12.5%.

[0056] Example 4: Screening of Taurine Ratios Weigh each raw material according to Table 7, fix the L-carnitine at 750 mg, use the same amount of compound B vitamins as in Examples 1-3, and adjust the taurine dosage to 200 mg (Example 4-1), 250 mg (Example 4-2), 350 mg (Example 4-3), and 400 mg (Example 4-4).

[0057] Table 7 Formulations of anti-fatigue effervescent tablets in Examples 4-1 to 4-4

[0058] The preparation method is the same as in Example 1.

[0059] The anti-fatigue effervescent tablets prepared in Examples 4-1 to 4-4 were tested using the same test method as in Example 1, and the results are shown in Table 8.

[0060] Table 8 Performance test results of Examples 4-1 to 4-4

[0061] As shown in Table 8, the taste deteriorates when the amount of taurine in tablets is increased to 400 mg. Therefore, the dosage of taurine is determined to be 200-350 mg.

[0062] Comparative Example 1 The raw material formulation is the same as in Examples 1-3, and the preparation method is as follows: Solid raw materials, including L-carnitine, taurine, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, sodium bicarbonate, microcrystalline cellulose, citric acid, apple powder, steviol glycosides, and maltodextrin, were dried in a vacuum drying oven at 50°C, with the moisture content of the materials controlled to be less than 0.5%. The materials were then passed through an 80-mesh sieve and accurately weighed.

[0063] Sodium bicarbonate, taurine, vitamins B1, B2, B3, B6, and B12, apple powder, citric acid, steviol glycosides, vitamin B5, and L-carnitine were mixed evenly and then passed through a 60-mesh sieve. This mixture was then combined with microcrystalline cellulose and purified water to prepare a wet effervescent mass. The wet granules were dried in a 50°C forced-air drying oven for 2 hours, maintaining a moisture content of <0.5%. The resulting dry granules were then sieved through a 20-mesh sieve for granulation. Maltodextrin was then added and mixed evenly. The mixture was then fed into a rotary tablet press to compress the effervescent tablets, with each tablet weighing 4g. The resulting effervescent tablets were then sealed and stored.

[0064] The anti-fatigue effervescent tablets prepared in Comparative Example 1 were tested using the same test method as in Example 1, and the results are shown in Table 9.

[0065] Table 9 Performance test results of Comparative Example 1-1

[0066] As shown in Table 9, conventional wet granulation, i.e., the one-pot method, results in severe sticking and compression during tableting due to the premature reaction between the acid and alkali sources during granulation, making it impossible to obtain intact tablets. This indicates that the acid-base two-phase separation granulation process used in this invention is one of the key technical means for successfully preparing the effervescent tablets.

[0067] Comparative Example 2: Comparison of different moisture control processes The raw material formula is the same as in Examples 1-3, and the preparation method is the same as in Example 1. The difference lies in the moisture control before granulation, as shown in Table 10.

[0068] Table 10 Moisture Control of Acid / Base Granules in Comparative Examples 2-1 to 2-3

[0069] The anti-fatigue effervescent tablets prepared in Comparative Example 2 were tested using the same testing method as in Example 1, and the results are shown in Table 11.

[0070] Table 11 Performance test results of comparative examples 2-1 to 2-3

[0071] Table 11 shows that when the moisture content of both acid and alkali granules before granulation is less than 0.5% (Comparative Example 2-1), there is no sticking or punching during tableting, and the tablets remain intact. However, when the moisture content of any granule is greater than 0.5% (Comparative Examples 2-2 and 2-3), sticking or punching occurs. Therefore, controlling the moisture content of both acid and alkali granules to below 0.5% is a key process parameter to avoid sticking and punching and ensure tablet integrity. Preferably, the moisture content of both acid and alkali granules is less than 0.5%, more preferably less than 0.3%.

[0072] Comparative Example 3 The difference from Examples 1-3 is that the formula does not contain compound vitamins, and the formula is shown in Table 12.

[0073] Table 12 Formulation of the anti-fatigue effervescent tablets in Comparative Example 3

[0074] The preparation process is the same as in Example 1.

[0075] Comparative Example 4 The difference from Examples 1-3 is that the formulation does not contain taurine, and the formulation is shown in Table 13.

[0076] Table 13 Formulation of the anti-fatigue effervescent tablets in Comparative Example 4

[0077] The preparation process is the same as in Example 1.

[0078] Verification example of the effect of anti-fatigue 1. Laboratory animals Ninety-eight SPF-grade Kunming mice, weighing 18–22 g, were raised in an environment with a temperature of (25±2)℃, humidity of 50%–60%, and alternating light and dark conditions for 12 hours.

[0079] 2 Experimental Methods After one week of acclimatization feeding, mice were subjected to a swimming test. Mice that swam abnormally were removed, and the remaining 90 mice were randomly divided into a control group and a control group according to their body weight. Mice in the treatment groups (Examples 1-1, 1-2, 1-3, 1-4, 4-1, 4-3, Comparative Example 3, and Comparative Example 4) were administered the drug by gavage daily. The dosage was calculated based on the human equivalent dose, and the equivalent dose for mice was approximately 4 × 0.0026 ÷ 0.02 ≈ 0.52 g / kg. Based on a weight of 20g per mouse, the dosage per mouse was 0.01g, administered once daily. Mice in the control group were administered an equal volume of purified water by gavage for 30 consecutive days. Their body weight was measured before administration (DO) and on days 6 (D6), 12, 18, 24, and 30 after administration.

[0080] Thirty minutes after the last administration of the drug, the mice were placed in a constant temperature swimming tank (50 cm × 50 cm × 40 cm) with a lead weight of 5% of their own body weight on the base of their tails. The mice were then swam in water at a depth of at least 30 cm and a temperature of 25°C. The experiment ended when the mice swam until their heads were submerged for 5 seconds and they no longer floated up. If a mouse was drowning, it should be rescued immediately. The time it took for the mouse to swim to exhaustion was recorded.

[0081] 3. Experimental Results 3.1 Effects on mouse body weight The effect of anti-fatigue effervescent tablets on mouse body weight: During the experimental period, the body weight of mice in each group increased compared with the initial body weight. At the end of the administration, compared with the weight of mice in the blank group, there was no statistically significant difference in body weight among mice in Examples 1-1, 1-2, 1-3, 1-4, 4-1, 4-3, Comparative Example 3, and Comparative Example 4 (P>0.05), as shown in Table 14.

[0082] Table 14 Effects of anti-fatigue effervescent tablets on mouse body weight (x±s, n=10)

[0083] 3.2 Effect on the time to exhaustion during weight-bearing swimming in mice Compared to the control group, Comparative Examples 3 and 4 showed a prolonged time to exhaustion during weight-bearing swimming in mice, but this was not statistically significant. Examples 1-1, 1-2, 1-3, 1-4, 4-1, and 4-3 showed a significantly prolonged time to exhaustion during weight-bearing swimming in mice (P<0.05). This indicates that the anti-fatigue effervescent tablets have an anti-fatigue effect because L-carnitine is responsible for the transport of fatty acids to mitochondria (energy production), taurine is responsible for cell membrane stability, and the complex vitamins enhance nutrition and promote metabolism; the three work synergistically (see Table 15).

[0084] Table 15 Effect of anti-fatigue effervescent tablets on the time to exhaustion during weight-bearing swimming in mice (x±s, n=10)

[0085] *Relative to the control group, p < 0.05 The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. An anti-fatigue effervescent tablet, characterized in that, The anti-fatigue effervescent tablets comprise, by weight: 40-100 parts L-carnitine, 15-38 parts taurine, 1-2 parts B complex vitamins, 40-100 parts binder, 35-55 parts disintegrant, 97.08-160.2 parts flavor modifier, and 35-65 parts filler.

2. The anti-fatigue effervescent tablet as described in claim 1, characterized in that, The anti-fatigue effervescent tablets comprise, by weight: 55-95 parts L-carnitine, 20-35 parts taurine, 1.15-1.48 parts B complex vitamins, 50-95 parts binder, 40-50 parts disintegrant, 105.1-149 parts flavor modifier, and 40-60 parts filler.

3. The anti-fatigue effervescent tablet as described in claim 1 or claim 2, characterized in that, The binder comprises one of microcrystalline cellulose, povidone K30, mannitol, polyvinylpyrrolidone, and hydroxypropyl methylcellulose; the flavor modifier comprises steviol glycosides, citric acid, and apple powder; the disintegrant comprises sodium bicarbonate; and the filler is maltodextrin.

4. The anti-fatigue effervescent tablet according to any one of claims 1 to 2, characterized in that, The complex B vitamins include 0.10-0.20 parts of vitamin B1, 0.070-0.080 parts of vitamin B2, 0.70-0.80 parts of vitamin B3, 0.20-0.30 parts of vitamin B5, 0.070-0.080 parts of vitamin B6, and 0.010-0.020 parts of vitamin B12.

5. The method for preparing anti-fatigue effervescent tablets as described in claims 1-4, characterized in that, include: Each solid raw material is dried until the moisture content is less than 0.5%, sieved, and weighed according to the proportion; Disintegrants, flavor modifiers, vitamin B12 and some binders are added to purified water to make a wet soft material, which is then dried until the moisture content is less than 0.5% to obtain alkali particles; The flavor modifier, taurine, L-carnitine, vitamin B1, vitamin B2, vitamin B3, vitamin B5 and vitamin B6 are mixed evenly, and then mixed evenly with some binder and purified water. After drying, they are pulverized until the moisture content is less than 0.5% to obtain acid granules. The acid and alkali granules are granulated, mixed, and then filled with filler and compressed into tablets to obtain the final product.

6. The preparation method according to claim 5, characterized in that, The drying temperature is 40~60℃.

7. The preparation method according to claim 5, characterized in that, The sieve used is a 70-90 mesh sieve.

8. The preparation method according to claim 5, characterized in that, The moisture content of both the dried acid and alkali particles is less than 0.3%.

9. The preparation method according to claim 5, characterized in that, After granulation, acid and alkali particles are passed through a 10-30 mesh sieve.

10. The use of the anti-fatigue effervescent tablet according to any one of claims 1 to 4 in the preparation of products for anti-fatigue purposes.

Images